Mizuho Securities analyst Steven Valiquette has maintained their bullish stance on HQY stock, giving a Buy rating today.
Steven Valiquette has given his Buy rating due to a combination of factors including Healthequity’s positive revenue guidance and the resilience of its core business fundamentals. Despite temporarily increased cybersecurity expenses, which have slightly impacted EBITDA and EPS projections, the overall financial outlook remains strong. The company’s revenue for the fiscal year 2026 has been revised upwards, reflecting confidence in its growth trajectory. Additionally, potential legislative changes could further expand the Health Savings Account market, providing a catalyst for future growth. Valiquette maintains a price target of $126, based on a discounted P/E multiple of 27x, which is conservative relative to the company’s historical average. This reflects a balanced view of current interest rate volatility while recognizing the company’s long-term growth potential.
According to TipRanks, Valiquette is a 2-star analyst with an average return of 0.0% and a 53.92% success rate. Valiquette covers the Healthcare sector, focusing on stocks such as Cencora, Healthequity, and Envista Holdings.
In another report released today, Barrington also reiterated a Buy rating on the stock with a $112.00 price target.